1Roigas J, Schulze G, Raytarowski S, et al. Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients. Urologe A, 2000, 39(6): 554-556.
2Kim CW, Kim JI, Park SH, et al. Usefulness of plasma tumor M2-pyruvate kinase in the diagnosis of gastrointestinal cancer. Korean J Gastroenterol, 2003, 42(5): 387-393.
3Mazurek S, Zwerschke W, Jansen-Durr P, et al. Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7. Oncogene, 2001, 20(47): 6891-6898.
4Schneider J, Neu K, Velcovsky HG, et al. Tumor M2-pyruvate kinase in the follow-up of inoperable lung cancer patients: a pilot study. Cancer Lett, 2003, 193(1): 91-98.
5Kaura B, Bagga R, Patel FD. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma. J Obstet Gynaecol Res, 2004, 30(3): 193-196.
6Roigas J, Deger S, Schroeder J, et al. Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma. Urol Res, 2003, 31(6): 358-362.
7Luftner D, Mazurek S, Henschke P, et al. Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer. Anticancer Res, 2003, 23(2A): 991-997.
8Hegele A, Varga Z, Kosche B, et al. Pyruvate kinase type tumor M2 in urological malignancies. Urol Int, 2003, 70(1): 55-58.
9Oremek GM, Muller R, Sapoutzis N, et al. Pyruvate kinase type tumor M2 plasma levels in patients afflicted with rheumatic diseases. Anticancer Res, 2003, 23(2A): 1131-1134.
10Oremek GM, Gerstmeier F, Sauer-Eppel H, et al. Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK). Anticancer Res, 2003, 23(2A): 1127-1130.
